Brief: Lonza Group Issues Exclusive License To Antharis Therapeutics To Advance Next-Generation Dual Payload ADCS For Gastrointestinal Cancers
15/06/2026 18:16
BRIEF-Lonza Group Issues Exclusive License To Antharis Therapeutics To Advance Next-Generation Dual Payload ADCS For Gastrointestinal Cancers June 15 (Reuters) - Lonza Group AG LONN.S:
LONZA GROUP AG - ISSUES EXCLUSIVE LICENSE TO ANTHARIS THERAPEUTICS TO ADVANCE NEXT-GENERATION DUAL PAYLOAD ADCS FOR GASTROINTESTINAL CANCERS
LONZA GROUP AG: UNDER TERMS OF AGREEMENT, ANTHARIS WILL SECURE RIGHTS TO LONZA'S DUAL-PAYLOAD ADC TECHNOLOGY PLATFORM
LONZA GROUP AG - LONZA WILL BE ELIGIBLE TO RECEIVE UPFRONT, POTENTIAL MILESTONE PAYMENTS AND ROYALTY PAYMENTS ON NET SALES.
Source text: ID:nPn7KlzcSa
Further company coverage: LONN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lonza AG
See all newsLonza buys 5 sites from Germany's Merck to more than double US footprint (updated)
Brief: Merck KGaA Confirms Divestment Of CDMO Business To Lonza
Lonza agrees to buy five US sites from Merck KGaA
Corrected: TABLE-Swiss trade surplus at CHF 4.35 bln in August (Sept. 17)
Table: Swiss trade surplus at CHF 1.31 bln in September